• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无进展生存期与总生存获益之间的关系:一项模拟研究。

Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation Study.

作者信息

Zhang Lijun, Ko Chia-Wen, Tang Shenghui, Sridhara Rajeshwari

机构信息

1 Division of Biometrics V, Office of Biostatistics, Office of Translational Sciences, Center of Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.

出版信息

Ther Innov Regul Sci. 2013 Jan;47(1):95-100. doi: 10.1177/0092861512459180.

DOI:10.1177/0092861512459180
PMID:30227487
Abstract

UNLABELLED

This study evaluated the circumstances under which the observed progression-free survival (PFS) benefit may translate into an overall survival (OS) benefit.

METHODS

A simulation study, based on PFS and OS joint model decomposition, was conducted to evaluate the impact of crossover rates, survival post progression (SPP) lengths, and magnitudes of difference in median PFS on OS. Under different simulation scenarios, the degree of impact was investigated based on the probability of observing a significant OS benefit given an observed PFS benefit.

RESULTS

Using simulation parameters defined based on historical NDA datasets, the probability of detecting an OS benefit given the observed PFS benefit depends largely on crossover rate and SPP length (ie, SPP median times). Compared to no crossover, a crossover rate of ≤ 50% decreases the probability of detecting an OS benefit by at most 15% regardless of the SPP length. A crossover rate of > 50% decreases the probability of detecting an OS benefit much further, and the extent of decrease is proportional to the length of SPP.

CONCLUSION

Crossover rate and SPP length are important factors affecting the benefit translating from PFS to OS. This simulation study identified a threshold, of 50%, for crossover rate that is likely to confound OS effect. With a greater than 50% crossover rate, longer SPP further decreases the probability of translating a PFS benefit to OS.

摘要

未标注

本研究评估了观察到的无进展生存期(PFS)获益转化为总生存期(OS)获益的情况。

方法

基于PFS和OS联合模型分解进行了一项模拟研究,以评估交叉率、进展后生存期(SPP)长度以及中位PFS差异幅度对OS的影响。在不同模拟场景下,根据在观察到PFS获益的情况下观察到显著OS获益的概率来研究影响程度。

结果

使用基于历史新药申请(NDA)数据集定义的模拟参数,在观察到PFS获益的情况下检测到OS获益的概率很大程度上取决于交叉率和SPP长度(即SPP中位时间)。与无交叉相比,无论SPP长度如何,交叉率≤50%最多可将检测到OS获益的概率降低15%。交叉率>50%会进一步降低检测到OS获益的概率,且降低程度与SPP长度成正比。

结论

交叉率和SPP长度是影响从PFS转化为OS获益的重要因素。本模拟研究确定了交叉率50%这一可能混淆OS效应的阈值。交叉率大于50%时,更长的SPP会进一步降低将PFS获益转化为OS的概率。

相似文献

1
Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation Study.无进展生存期与总生存获益之间的关系:一项模拟研究。
Ther Innov Regul Sci. 2013 Jan;47(1):95-100. doi: 10.1177/0092861512459180.
2
Verification of the correlation between progression-free survival and overall survival considering magnitudes of survival post- progression in the treatment of four types of cancer.考虑四种癌症治疗中进展后生存幅度的无进展生存期与总生存期之间相关性的验证。
Asian Pac J Cancer Prev. 2015;16(3):1001-6. doi: 10.7314/apjcp.2015.16.3.1001.
3
Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study.在当今肿瘤学领域存在无进展生存期获益的情况下解读总生存期结果:转移性肾细胞癌病例研究。
Cancer Manag Res. 2014 Sep 22;6:365-71. doi: 10.2147/CMAR.S67249. eCollection 2014.
4
Detecting an overall survival benefit that is derived from progression-free survival.检测从无进展生存中获得的总生存获益。
J Natl Cancer Inst. 2009 Dec 2;101(23):1642-9. doi: 10.1093/jnci/djp369. Epub 2009 Nov 9.
5
Detecting overall survival benefit derived from survival postprogression rather than progression-free survival.检测从疾病进展后生存而非无进展生存中获得的总生存获益。
J Natl Cancer Inst. 2015 May 8;107(8). doi: 10.1093/jnci/djv133. Print 2015 Aug.
6
Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure.一线治疗失败后接受抗癌药物治疗的晚期非小细胞肺癌患者的无进展生存期与总生存期的关系。
Asia Pac J Clin Oncol. 2015 Jun;11(2):121-8. doi: 10.1111/ajco.12199. Epub 2014 May 9.
7
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.伊立替康、奥沙利铂和雷替曲塞用于治疗晚期结直肠癌:系统评价与经济学评估
Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. doi: 10.3310/hta12150.
8
Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?现代临床试验中无进展生存期与总生存期的相关性较差:复合终点是答案吗?
Eur J Cancer. 2012 Feb;48(3):385-8. doi: 10.1016/j.ejca.2011.10.028. Epub 2011 Nov 22.
9
Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis.慢性淋巴细胞白血病无进展生存期与总生存期的关系:基于文献的分析
Curr Oncol. 2015 Jun;22(3):e148-56. doi: 10.3747/co.22.2119.
10

引用本文的文献

1
Improving Collection and Analysis of Overall Survival Data.改善总生存数据的采集和分析。
Clin Cancer Res. 2024 Sep 13;30(18):3974-3982. doi: 10.1158/1078-0432.CCR-24-0919.
2
A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression.一种用于设计测试总生存期的临床试验的多状态模型,该模型允许进展后交叉。
Stat Biopharm Res. 2016;8(1):12-21. doi: 10.1080/19466315.2015.1093539. Epub 2016 Mar 22.
3
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials.
转移性黑色素瘤中总生存期的替代终点:随机对照试验的荟萃分析。
Lancet Oncol. 2014 Mar;15(3):297-304. doi: 10.1016/S1470-2045(14)70007-5. Epub 2014 Jan 31.